Among the mechanisms responsible for primary or acquired resistance to endocrine therapies is the loss of estrogen and/or progesterone receptor expression, which may render breast cancer cells independent of estrogen stimulation and, consequently, resistant to estrogen deprivation or pharmacological inhibition of estrogen receptors. Here, ESR1 is linked to breast cancer.